Recent Advances in the Application of Cucurbitacins as Anticancer Agents

Abstract

Cucurbitacins are tetracyclic triterpenoid secondary metabolites, widely distributed in the Cucurbitaceae family. These bitter-tasting compounds act primarily as defense mechanisms against external injuries, and thus against herbivores, and furthermore, they have also found use in folk medicine in the treatment of various diseases. Many studies have acknowledged significant biological activities of cucurbitacins, such as antioxidant and anti-inflammatory activities, antimicrobial properties, or antitumor potential. Overall, cucurbitacins have the ability to inhibit cell proliferation and induce apoptosis in various cancer cell lines. Both in vitro and in vivo studies were performed to evaluate the anticancer activity of varied cucurbitacins. Cucurbitacins offer a promising avenue for future cancer treatment strategies, and their diverse mechanisms of action make them attractive candidates for further investigation. The aim of the present study is to shed light on the chemical diversity of this group of compounds by providing the sources of origin of selected compounds and their chemical structure, as well as insight into their anticancer potential. In addition, within this paper molecular targets for cucurbitacins and signalling pathways important for cancer cell proliferation and/or survival that are affected by the described class of compounds have been presented.

Terpenoid-Mediated Targeting of STAT3 Signaling in Cancer: An Overview of Preclinical Studies

“…It has been discovered that there are more than 18 different types of cucurbitacin, with cucurbitacin B being a common kind [144]. CuB has been shown to activate apoptosis in various cancer types via the signaling pathways of Wnt/β-catenin, JAK/STAT, NF-κB, PI3K/AKT, and MAPK/ERK [145,146]. Cucurbitacin B induced growth inhibition and apoptosis in pancreatic cancer cells in a dose-and time-responsive manner [93].…”